GRCL / Orbimed Advisors Now Owns 11.2% of Gracell Biotechnologies

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA more_horizontal

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a gl more_horizontal

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob more_horizontal

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants William Cao - Chairman, C more_horizontal

Gracell Biotechnologies is a clinical-stage biotech company based in China. The company's lead therapy is in four different trials to treat various di more_horizontal

SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob more_horizontal

Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug more_horizontal

Two analysts upgraded their ratings for Gracell Biotechnologies' stock. Over the weekend, Gracell announced positive follow-up trial data regarding it more_horizontal